

Appl. No. : 09/918,026  
Filed : July 30, 2001

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

#### LISTING OF CLAIMS

1. (Currently Amended) An antisense oligonucleotide ~~8 to 50~~ 12 to 30 nucleobases in length targeted to the coding region of a nucleic acid molecule encoding human acyl CoA cholesterol acyltransferase-2 (SEQ ID NO: 3), wherein said antisense oligonucleotide specifically hybridizes with said region and inhibits the expression of a nucleic acid molecule encoding acyl CoA cholesterol acyltransferase-2 by at least ~~60%~~ 55%.
2. (Canceled)
3. (Canceled)
4. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified internucleoside linkage.
5. (Previously Presented) The antisense oligonucleotide of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified sugar moiety.
7. (Previously Presented) The antisense oligonucleotide of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Previously Presented) The antisense oligonucleotide of claim 1 which comprises at least one modified nucleobase.
9. (Previously Presented) The antisense oligonucleotide of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Previously Presented) The antisense oligonucleotide of claim 1 which is a chimeric oligonucleotide.
11. (Canceled)
12. (Previously Presented) A composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a

**Appl. No.** : **09/918,026**  
**Filed** : **July 30, 2001**

colloidal dispersion system.

14-20. (Canceled)

**Appl. No.** : **09/918,026**  
**Filed** : **July 30, 2001**

## **SUMMARY OF INTERVIEW**

### Identification of Claims Discussed

All of the pending claims were discussed.

### Principal Arguments and Other Matters

Applicant's representatives discussed the pending Office Action and the issues raised by the Examiner with regard to the 103(a) and written description rejections.

### Results of Interview

It was agreed that if Applicant provides a reference that discusses reasons for not targeting ACAT-1 (e.g. toxicity reasons), the 103 are rejection of record would be overcome. Furthermore, it was agreed that deleting "60%" from claim 1 and adding a range of nucleotides would overcome the written description rejection.